XFOR — X4 Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $97.40m
- $71.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 163.72 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -130.31% | ||
| Return on Equity | -489.12% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 3 | n/a | n/a | n/a | 6.26 | 51.28 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Directors
- Michael Wyzga NEC (66)
- Paula Ragan PRE (51)
- Adam Mostafa CFO (41)
- Mary Dibiase COO (60)
- Arthur Taveras CSO (57)
- Karolyn Park VPR
- Derek Meisner GCN (50)
- Diego Cadavid OTH (55)
- Gary Bridger DRC (58)
- Francoise De Craecker DRC
- William Aliski IND (73)
- Alison Lawton IND (60)
- David McGirr IND (66)
- Murray Stewart IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- August 2nd, 2010
- Public Since
- November 16th, 2017
- No. of Shareholders
- 60
- No. of Employees
- 93
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 167,937,781
- Address
- 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, 02134
- Web
- https://www.x4pharma.com/
- Phone
- +1 8575298300
- Contact
- Daniel Ferry
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for XFOR
Q2 2024 X4 Pharmaceuticals Inc Earnings Release
Q3 2024 X4 Pharmaceuticals Inc Earnings Release
Similar to XFOR
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the X4 Pharmaceuticals share price?
As of Today at 24:13 UTC, shares in X4 Pharmaceuticals are trading at $1.01. This share price information is delayed by 15 minutes.
How has the X4 Pharmaceuticals share price performed this year?
Shares in X4 Pharmaceuticals last closed at $1.01 and the price had moved by -48.99% over the past 365 days. In terms of relative price strength the X4 Pharmaceuticals share price has underperformed the S&P500 Index by -59.41% over the past year.
What are the analyst and broker recommendations for X4 Pharmaceuticals?
The overall consensus recommendation for X4 Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the X4 Pharmaceuticals dividend yield?
X4 Pharmaceuticals does not currently pay a dividend.
Does X4 Pharmaceuticals pay a dividend?
X4 Pharmaceuticals does not currently pay a dividend.
When does X4 Pharmaceuticals next pay dividends?
X4 Pharmaceuticals does not currently pay a dividend.
How do I buy X4 Pharmaceuticals shares?
To buy shares in X4 Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of X4 Pharmaceuticals?
As of the previous close price of $1.01, shares in X4 Pharmaceuticals had a market capitalisation of $169.62m.
Where are X4 Pharmaceuticals shares listed?
Here are the trading details for X4 Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: XFOR
What kind of share is X4 Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum X4 Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a X4 Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in X4 Pharmaceuticals is $4.12. That is 307.92% above the last closing price of $1.01.
Analysts covering X4 Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.55 for the next financial year.
What is the trend in the X4 Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like X4 Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +21.99%.
As of the last closing price of $1.01, shares in X4 Pharmaceuticals were trading +4.96% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the X4 Pharmaceuticals PE Ratio?
The X4 Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of X4 Pharmaceuticals?
X4 Pharmaceuticals' management team is headed by:
- Michael Wyzga - NEC
- Paula Ragan - PRE
- Adam Mostafa - CFO
- Mary Dibiase - COO
- Arthur Taveras - CSO
- Karolyn Park - VPR
- Derek Meisner - GCN
- Diego Cadavid - OTH
- Gary Bridger - DRC
- Francoise De Craecker - DRC
- William Aliski - IND
- Alison Lawton - IND
- David McGirr - IND
- Murray Stewart - IND